The Mayo Clinic through the vehicle of the North Central Cancer Treatment Group (NCCTG) will serve as primary research base for the following CCOP's: Alton Ochsner Medical Foundation, Carle Cancer Center, Cedar Rapids Oncology Project, the Duluth Clinic, Geisinger Clinic nd Medical Center, Illinois Oncology Research Association, Iowa Oncology Research, Association Rapid City Regional Oncology Group, St. Luke's Hospitals, Sioux Community Cancer Consortium, and Toledo. We will also serve as research base for cancer control protocol activity of non-CCOP participants and for the multiple CCOP's outside of our group who contribute to intergroup cancer treatment and cancer control protocols which we lead. We will cooperate with our affiliated CCOP's in planning their program and in conducting appropriate continuing education and workshops. We will provide training and active support for their data managers and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. This will include evolving and maintaining standard reporting procedures for surgery, pathology, and radiation therapy. We will hold regular meetings of the CCOP's for review of ongoing research, planning future research, and for related professional activities. We will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP performance not only by timely review of patient data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic randomly scheduled monitoring site visits. We will work with each CCOP participant to aid in their maturation as clinical investigators. We will assist them in developing new protocols for which they will share leadership and we will work with them in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide them with justifiable pride in their participation in the National Cancer Program. A high priority over this grant period will be expansion of our control efforts into cancer prevention with incorporation of associated basic laboratory support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037404-09
Application #
3558053
Study Section
Special Emphasis Panel (SRC (48))
Project Start
1983-09-15
Project End
1996-05-31
Budget Start
1993-06-01
Budget End
1994-05-31
Support Year
9
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Tan, A D; Novotny, P J; Kaur, J S et al. (2016) QOL and Survival Comparisons by Race in Oncology Clinical Trials. J Cancer Clin Oncol 2:
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Crozier, Jennifer A; Advani, Pooja P; LaPlant, Betsy et al. (2016) N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 16:23-30
Kadakia, Kunal C; Loprinzi, Charles L; Atherton, Pamela J et al. (2016) Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Support Care Cancer 24:1061-9

Showing the most recent 10 out of 377 publications